Topic: Deena Beasley
NEW YORK (Reuters) - A closely watched experimental hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal late-stage trial of previously untreated patients, the company said on Tuesday.The results from the first ...
